Modeling Huntington’s

Non-profit organization High Q Foundation
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HOUSTON—Non-profit organization High Q Foundation announced it had entered into a two-year R&D collaboration with Stem Cell Innovations (SCI) for the development of Huntington's disease cell model for drug discovery. The deal revolves on the application of SCI's PluriCell platform, and will see SCI receive $1.1 million on completion of certain milestones. The company also has the right to further use, develop, and commercialize any products arising.
 
"This agreement will allow us to accelerate our efforts in generating a unique panel of human neurodegenerative disease models, which will be integral in the further development of our potential products," says SCI CEO Dr. James Kelly.
 
Derived from fetal gonadal cells, PluriCells do not come with the culturing challenges associated with standard embryonic stem cells, according to SCI. Within the past year, SCI has signed similar collaborations with agencies and companies looking at everything from ALS to bone morphogenesis to cardiomyopathy.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue